The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.